A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects.
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2015
At a glance
- Drugs Pramlintide (Primary) ; Phentermine; Sibutramine
- Indications Obesity; Weight loss
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 21 Jan 2010 Results published in Obesity.
- 07 Sep 2008 Results presented at the 44th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Jun 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History